Barış Kırat

Barış Kırat

Auto-generated profile, based on publicly available information

Barış Kırat

Department of Anesthesiology and Reanimation, Medicana International Istanbul Hospital , Istanbul, 34520

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
MAmustafa kemal Avsar
mustafa kemal Avsar
YGYasin Güzel
Yasin Güzel
IÖİbRahim Özgür Önsel
İbRahim Özgür Önsel
BKBarış Kırat
Barış Kırat
IYİlKer Kemal Yücel
İlKer Kemal Yücel
DYDeniz Yorgancılar
Deniz Yorgancılar
Background: The extracardiac Fontan procedure, a palliative intervention for single‐ventricle physiology, is associated with significant thromboembolism and bleeding risks. Warfarin has been the standard anticoagulant, but its limitations have prompted exploration of nonvitamin K oral anticoagulants, such as rivaroxaban. Objective: To compare the safety and efficacy of rivaroxaban vs. warfarin as postoperative anticoagulation in pediatric patients following the extracardiac Fontan procedure, focusing on thromboembolic events, bleeding complications, and treatment adherence. Methods: This retrospective cohort study included 369 pediatric patients (aged 3–17 years) who underwent the extracardiac Fontan procedure at a single center from 2015 to 2022, selected from 412 cases reviewed, with 43 excluded due to incomplete follow‐up or comorbidities. Patients received either warfarin ( n = 177) or rivaroxaban ( n = 192) for anticoagulation. Baseline characteristics, including age, sex, body weight, and pulmonary artery pressure, were comparable between groups. Anticoagulation was initiated on postoperative Day 1 per institutional protocol, excluding aspirin to standardize thromboembolism prevention due to high risk in nonanticoagulated patients. Warfarin was titrated to an international normalized ratio (INR) of 2.0–3.0, while rivaroxaban was dosed per European Medicines Agency guidelines. Outcomes included thromboembolic events (graft thrombosis, pulmonary embolism, and transient ischemic attacks [TIAs]), major and minor bleeding, mortality, and treatment discontinuation over a mean follow‐up of 5 years. TIAs were defined per American Heart Association guidelines as transient neurological dysfunction lasting less than 24 h without infarction on neuroimaging. Statistical analyses used Fisher’s exact test, Kaplan–Meier survival analysis, and multivariable logistic regression, with p < 0.05 indicating significance; the study was designed to detect a 3% difference in major bleeding. The limited number of thromboembolic events resulted in wide confidence intervals, limiting precision in between‐group comparisons. Results: Thromboembolic events occurred in 5.1% ( n = 9) of warfarin patients and 2.1% ( n = 4) of rivaroxaban patients (OR = 2.5, 95% CI: 0.8–8.2). Major bleeding was significantly higher with warfarin (3.4%, n = 6; 4 intracranial and 2 gastrointestinal) than rivaroxaban (0.5%, n = 1; gastrointestinal; OR = 7.0, 95% CI: 1.2–40.8). Minor bleeding rates were 9.0% (warfarin) vs. 5.7% (rivaroxaban). Two warfarin‐related deaths (intracranial hemorrhage and systemic embolism post‐TIA) were recorded; none occurred with rivaroxaban. Treatment discontinuation was higher with warfarin (5.1% vs. 0.5%). Conclusions: Rivaroxaban demonstrated a superior safety profile compared to warfarin, with significantly lower major bleeding rates, no associated mortality, and improved treatment adherence in pediatric Fontan patients. Its fixed‐dose regimen simplifies management, although implementation requires consideration of cost and formulation access. Risk‐stratified approaches and larger prospective trials are needed to optimize anticoagulation strategies.

5 September 2025 in Cardiology in the Young
Verified
Journal Article
Open access
PDF file
MAmustafa kemal Avsar
mustafa kemal Avsar
DBDr Ramush Bejiqi
Dr Ramush Bejiqi
YGYasin Güzel
Yasin Güzel
CZCenap Zeybek
Cenap Zeybek
BKBarıs Kirat
Barıs Kirat
MBMehmet Salih Bilal
Mehmet Salih Bilal
Objective: Chronic pulmonary regurgitation following tetralogy of Fallot repair burdens the right ventricle. This study evaluated early outcomes of pulmonary valve reconstruction using right atrial tissue versus standard transannular patch repair.Methods: A retrospective analysis of 412 tetralogy of Fallot patients (2014–2024) was conducted: Atrial Valve Group (n = 205) underwent valve reconstruction; No-Valve Group (n = 207) received standard repair. Patients were followed for 1 year with echocardiographic assessments. Outcomes included right ventricular insufficiency, ventilation duration, and ICU stay.Results: Atrial Valve Group had lower right ventricular insufficiency at 12 months (9.3% vs. 19.8%, p = 0.004, OR = 2.39, 95% CI: 1.32–4.33), shorter ventilation times (6.1 vs. 18.0 hours, p < 0.001, Cohen’s d = 3.54), and reduced ICU stays (3.0 vs. 5.7 days, p < 0.001, Cohen’s d = 1.87), despite longer CPB durations (47.1 vs. 40.5 minutes, p = 0.02).Conclusions: Right atrial tissue reconstruction reduces early and intermediate-term right ventricular dysfunction post-tetralogy of Fallot repair. Long-term studies are needed.

1 April 2026 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
OBOnur Benli
Onur Benli
MAmustafa kemal Avsar
mustafa kemal Avsar
AŞAhmet Şen
Ahmet Şen
IÖİbRahim Özgür Önsel
İbRahim Özgür Önsel
BKBarış Kırat
Barış Kırat
CZCenap Zeybek
Cenap Zeybek
Objectives: To report early and mid-term outcomes after extracardiac total cavopulmonary connection (EC-TCPC) and to evaluate prespecified subgroup comparisons, including calendar-time era effects (Era I vs Era II), selective fenestration, conduit-size categories, and late-era computational fluid dynamics (CFD)-guided conduit sizing. Methods: This multicentre retrospective cohort study included 788 patients who underwent EC-TCPC between 2009 and 2025. Patients were prespecified into Era I (2009-2016) and Era II (2017-2025) for calendar-time comparisons reflecting evolving pathway-based management; the CFD-guided subcohort was restricted to late-era patients. Survival and event-related outcomes were analysed using Kaplan-Meier, competing-risk methods, and multivariable regression models. Results: Early mortality was 2.4%. During a median follow-up of 8.2 years, overall survival was 97.2% at 1 year, 95.0% at 5 years, and 92.5% at 10 years. Freedom from major adverse events (MAEs) was 95.6%, 84.3%, and 75.3% at the same time points; the 10-year cumulative incidence of thromboembolism was 6.8% and of MAEs was 23.6%. In the prespecified era comparison, Era II was associated with shorter pleural drainage duration and lower rates of prolonged pleural effusion. Fenestrated patients showed higher event rates, consistent with confounding by indication. In Era II, CFD-guided conduit sizing was associated with improved early postoperative haemodynamics but did not independently reduce mid-term clinical events after adjustment. Conclusions: A physiology-driven extracardiac Fontan strategy provides low early mortality and preserved mid-term survival. Selective fenestration and geometry-aware conduit sizing support individualized surgical planning, whereas CFD-guided optimization should be regarded as a decision-support tool rather than a causal determinant of outcome.

1 January 2025 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
MAmustafa kemal Avsar
mustafa kemal Avsar
YGYasin Güzel
Yasin Güzel
IÖİbRahim Özgür Önsel
İbRahim Özgür Önsel
BKBarış Kırat
Barış Kırat
IYİlKer Kemal Yücel
İlKer Kemal Yücel
DYDeniz Yorgancılar
Deniz Yorgancılar
Objective: This study compared early postoperative outcomes of Custodiol‐HTK versus cold intermittent blood cardioplegia in patients undergoing complete atrioventricular septal defect (CAVSD) repair. Methods: From January 2012 to December 2022, we retrospectively analyzed 305 patients undergoing CAVSD repair at our center. Patients were divided into two groups based on cardioplegia: Group 1 received Custodiol‐HTK ( n = 159), and Group 2 received cold intermittent blood cardioplegia ( n = 146). Outcomes that were compared included mortality, ECMO requirement, cross‐clamp and cardiopulmonary bypass (CPB) times, cardioplegia doses, valvular edema (assessed intraoperatively via a visual scale), postoperative intubation time, ICU stay, and hospital stay. Results: Mortality was 1.9% in Group 1 versus 8.2% in Group 2 ( p = 0.01). ECMO was required in 0.6% of Group 1 versus 11.0% of Group 2 ( p < 0.001). Cross‐clamp time (56 ± 12 min vs. 76 ± 16 min, p < 0.001) and CPB time (83 ± 14 min vs. 97 ± 17 min, p = 0.002) were shorter in Group 1. Cardioplegia doses were 1 in Group 1 versus 4.7 ± 1.2 in Group 2 ( p < 0.001). Intubation time, ICU stay, and hospital stay were significantly shorter in Group 1 ( p < 0.01 for each). Conclusion: Custodiol‐HTK was associated with improved early outcomes, including reduced mortality, ECMO use, and shorter operative and recovery times, in CAVSD repair. It appears to offer superior myocardial protection, particularly in complex cases, though potential risks such as hyponatremia require careful perioperative management.

1 January 2026 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
PDF file
MAmustafa kemal Avsar
mustafa kemal Avsar
OBOnur Benli
Onur Benli
IÖİbRahim Özgür Önsel
İbRahim Özgür Önsel
BKBarış Kırat
Barış Kırat
CBCarl Britto
Carl Britto
CZCenap Zeybek
Cenap Zeybek
Background: Residual and additional (previously unrecognized) ventricular septal defects (VSDs) can complicate pediatric congenital heart surgery and may necessitate early reintervention. We evaluated the intraoperative detection yield and safety of left atrial saline flooding as a practical adjunct to intraoperative transesophageal echocardiography (TEE) in a large multicenter cohort. Methods: We retrospectively analyzed 2739 pediatric patients (mean age 2.6 years; 51% male) undergoing repair of isolated VSD ( n = 1252), atrioventricular septal defect (AVSD; n = 644), or tetralogy of Fallot (TOF; n = 843) at four tertiary centers in Türkiye (2000–2023). Left atrial saline flooding was performed via a patent foramen ovale when present or a limited atrial septotomy when required, before separation from cardiopulmonary bypass (CPB), and used alongside intraoperative TEE. Mean additional CPB time attributable to the maneuver was 5 ± 1 min. Results: Saline flooding identified residual VSDs in 163 patients (5.9%) and additional VSDs in 218 patients (8.0%), with rates differing significantly by diagnosis (highest in AVSD: 12.6% residual and 16.0% additional; p < 0.001 across groups). All detected defects were revised immediately during the index operation. Discharge echocardiography showed 10 trivial residual shunts (0.36%), none requiring intervention. No complications were attributed to the saline flooding maneuver. Postoperative adverse events included prolonged mechanical ventilation (1.7%), arrhythmias (2.4%), and superficial surgical site infection (0.9%). Operative mortality, defined according to Society of Thoracic Surgeons (STS) criteria as death occurring during the index hospitalization or within 30 days postoperatively, was 0.29% ( n = 8; AVSD: 5, TOF: 3). No surgical reoperation or transcatheter procedure was performed for residual/additional VSD closure during follow‐up. Conclusions: Left atrial saline flooding is a safe, low‐cost, and reproducible adjunct that can facilitate intraoperative identification and immediate correction of residual and additional VSDs prior to separation from CPB. Routine use may strengthen intraoperative quality control and reduce clinically significant residual shunting after pediatric congenital heart repairs.